Module 7: Pharmacoeconomic Outcomes of Suboptimal LDL-C Management

Module 7: Pharmacoeconomic Outcomes of Suboptimal LDL-C Management

This CME-accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9).

Target Audience

These activities have been designed to meet the educational needs of interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia.

Educational Objectives 

Upon completion of these activities, participants should be better able to do the following:

  1. Discuss the pharmacoeconomic implications of managed care access and barriers to novel nonstatin medications

Faculty

Deepak L. Bhatt, MD, MPH
Professor of Medicine
Harvard Medical School
Executive Director, Interventional Cardiovascular Programs
Brigham and Women’s Hospital
Senior Investigator, Thrombolysis in Myocardial Infarction Study Group
Boston, Massachusetts

Sergio Fazio, MD, PhD
The William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology

Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of these educational activities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:

Name of Faculty or Presenter

Relationship Identified With:

Deepak L. Bhatt, MD, MPH

Grant/Research: Abbott Laboratories, Amarin Corporation, Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Chiesi USA, Inc., Eisai Inc., Ethicon US, LLC, Forest Laboratories, Inc., Ironwood Pharmaceuticals, Inc., Ischemix, Inc., Eli Lilly and Company, Medtronic PLC, Pfizer Inc., F. Hoffmann-La Roche Ltd, sanofi-aventis U.S. LLC, The Medicines Company
Sergio Fazio, MD, PhDConsultant/Advisor: Aegerion Pharmaceuticals, Amarin Corporation, Ackea Therapeutics, Inc., Amgen Inc., Kowa Pharmaceuticals America, Inc.

Non-faculty: Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.

Financial Support

These activities have been supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications in collaboration with the American Journal of Cardiology.

                                      

CME Credit (Physicians)

These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Elsevier Office of Continuing Medical Education, Integritas Communications, and Sanofi US and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician
Course opens: 
10/23/2018
Course expires: 
10/22/2019
Rating: 
0

Available Credit

  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician

Accreditation Period

Course opens: 
10/23/2018
Course expires: 
10/22/2019
Please login or register to take this course.